AUS
NZ
UK
CA
USA
IND
Highlights:
- Wilsons Advisory has appointed Dr Bryan Tan as head of healthcare in corporate finance and Rita Fung as a healthcare analyst.
- Dr Tan brings extensive experience from Medical Developments International, AstraZeneca, and GenesisCare, with a continued part-time ER practice.
- Fung will lead healthcare sector research with prior experience at RBC Capital Markets, Pendal Group, and First State Super.
Wilsons Advisory has strengthened its healthcare coverage by appointing experienced professionals in corporate finance and equity research. The firm has brought on Dr Bryan Tan as head of healthcare in corporate finance and Rita Fung as a healthcare analyst, reinforcing its commitment to healthcare sector expansion.
Dr Tan, previously with MST Financial, has held significant roles at Medical Developments International (ASX:MVP), AstraZeneca, GenesisCare, and Johnson & Johnson. He has also contributed to projects at VML Health. While assuming his new responsibilities at Wilsons Advisory, he is expected to continue practicing as an emergency room physician a few days a month. Dr Tan's responsibilities at Wilsons Advisory include advising clients on mergers and acquisitions and capital raisings for ASX-listed healthcare companies and emerging growth opportunities.
Wilsons Advisory's head of corporate finance, Rob Snow, emphasized Dr Tan’s diverse expertise, stating that his background as a physician and senior pharmaceutical executive provides valuable insights for clients in the healthcare sector.
Alongside Dr Tan’s appointment, Rita Fung has joined as a healthcare analyst and will focus on leading research coverage within the healthcare industry. With experience from RBC Capital Markets, Pendal Group, and First State Super, Fung's analytical capabilities are set to enhance Wilsons Advisory’s research initiatives. She will collaborate closely with Dr Shane Storey to provide comprehensive insights into the sector.
Wilsons Advisory’s research head, James Ferrier, highlighted the significance of the healthcare sector in Australia, acknowledging the country’s contributions to global healthcare innovations. He noted that Fung’s extensive understanding of the healthcare industry will be instrumental in delivering valuable insights to clients.
These appointments reflect Wilsons Advisory's strategic focus on expanding its presence in the healthcare sector, capitalizing on growth opportunities within ASX-listed companies such as CSL Limited (ASX:CSL), ResMed Inc. (ASX:RMD), and Cochlear Limited (ASX:COH). The firm aims to leverage the extensive expertise of its new hires to drive strategic initiatives and support clients in navigating the evolving healthcare landscape.
With an increasing emphasis on healthcare investments and innovation, Wilsons Advisory continues to position itself as a key player in the financial advisory sector, providing specialized services tailored to the unique challenges and opportunities within the healthcare industry.
